Ireland

Nabriva Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

IRELAND Ireland

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Lefamulin Demonstrates Anti-Inflammatory Activity in Pre-Clinical Study

Lead Product(s): Lefamulin Acetate

Therapeutic Area: Infections and Infectious Diseases Product Name: Xenleta

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 23, 2020

Details:

In pre-clinical model, lefamulin shows anti-inflammatory activity comparable to dexamethasone.

Nabriva Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

IRELAND Ireland

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

XENLETA® (lefamulin) Receives Health Canada Approval for Treatment of Community Acquired Pneumonia

Lead Product(s): Lefamulin Acetate

Therapeutic Area: Infections and Infectious Diseases Product Name: Xenleta

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 16, 2020

Details:

Nabriva Therapeutics has received approval from Health Canada to market oral and intravenous (IV) formulations of XENLETA® (lefamulin) for the treatment of community-acquired pneumonia (CAP) in adults.

Nabriva Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

IRELAND Ireland

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Nabriva Therapeutics Enters into Exclusive Agreement to Promote and Distribute SIVEXTRO® (tedizolid phosphate) in the U.S.

Lead Product(s): Tedizolid Phosphate

Therapeutic Area: Infections and Infectious Diseases Product Name: Sivextro

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Merck & Co. Inc.

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement July 15, 2020

Details:

Under the terms of the agreement, Nabriva will procure SIVEXTRO from Merck & Co. Inc., Kenilworth, N.J., USA and be responsible for marketing, sales, and distribution of SIVEXTRO in the U.S. through December 31, 2023, with renewable three-year extensions.

Nabriva Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

IRELAND Ireland

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

WEP Clinical Partners With Nabriva Therapeutics for the Named Patient Supply of XENLETA® (lefamulin)

Lead Product(s): Lefamulin Acetate

Therapeutic Area: Infections and Infectious Diseases Product Name: Xenleta

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: WEP

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership July 06, 2020

Details:

Under the terms of the NPP, XENLETA will be made available in 2 formulations - 150mg injection for IV administration and 600mg oral tablets - using named patient or expanded access managed by WEP to enable healthcare professionals to access XENLETA to meet clinical needs.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Nabriva Therapeutics

Lefamulin Demonstrates Anti-Inflammatory Activity in Pre-Clinical Study

Nabriva Therapeutics

XENLETA® (lefamulin) Receives Health Canada Approval for Treatment of Community Acquired Pneumonia

Nabriva Therapeutics

Nabriva Therapeutics Enters into Exclusive Agreement to Promote and Distribute SIVEXTRO® (tedizolid phosphate) in the U.S.

Nabriva Therapeutics

WEP Clinical Partners With Nabriva Therapeutics for the Named Patient Supply of XENLETA® (lefamulin)